Vamos aos artigos científicos, aos factos e aos números oficiais.
Cerca de 50% da população apresenta imunidade cruzada ao SARS-Cov-2,
conferida pelas células T, de acordo com os artigos científicos "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals", "SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls", entre outros.
No artigo científico "Infection fatality rate of COVID-19 inferred from seroprevalence data", publicado no Bulletin of the World Health Organization, afirma-se que «
In people <70 years, infection fatality rates ranged from 0.00% to 0.31% with crude and corrected medians of 0.05%.» e «If one could sample equally from all locations globally, the
median infection fatality rate might be even substantially lower than the 0.23% observed in my analysis.», valor este corrigido para 0,15% em Abril último."The [Moderna, Pfizer]
COVID-19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) ..."
"The US-developed COVID-19 vaccine was rubber-stamped by the European Commission after
getting conditional market approval from the EU's medical watchdog. "
Dito de outra forma: trata-se de vacinas experimentais administradas a cobaias humanas, cujos ensaios clínicos se vão prolongar até 2023, desconhecendo-se para já os efeitos de médio e longo termo.No artigo científico "Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials", dá-se conta que «The absence of reported absolute risk reduction in COVID-19 vaccine clinical trials can lead to outcome reporting bias that affects the interpretation of vaccine efficacy. (...)
Unreported absolute risk reduction measures of 0.7% and 1.1% for the Pfzier/BioNTech and Moderna vaccines, respectively, are very much lower than the reported relative risk reduction measures. Reporting absolute risk reduction measures is essential to prevent outcome reporting bias in evaluation of COVID-19 vaccine efficacy.»
Dito de outra forma: para as vacinas mencionadas,
os vacinados apresentam apenas uma redução de risco de contrair a doença, relativamente aos não-vacinados, à volta de 1%.